نتایج جستجو برای: gleevec

تعداد نتایج: 513  

Journal: :Sarcoma 2007
Elizabeth M. Pinder Gurprit S. S. Atwal Abraham A. Ayantunde Sarah Khan Mike Sokal Tom McCulloch Simon L. Parsons

Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups...

Background and Aims: Detection of overexpression in tumor-inhibiting genes provides valuable information for leukemia diagnosis and prognosis. Chronic myeloid leukemia (CML) is a stem cell disorder determined by a well-defined genetic anomaly involving BCR-ABL translocation in the Philadelphia chromosome. Curcumin is a chemo-preventive agent for the primary cancer targets, such as the breast, p...

Journal: :International journal of oncology 2007
Ofer Merimsky Yaara Gorzalczany Ronit Sagi-Eisenberg

Drug combinations may provide a therapeutic benefit in treating cancer patients. However when considering a drug combination, it is important to assess how the molecular impact of the combination relates to the effects manifested by each drug alone and whether or not it varies depending on the tumor type. In this study, we have analyzed the molecular impact on a human leiomyosarcoma cell line (...

Journal: :American journal of clinical pathology 2007
Ana L Gomes Ricardo H Bardales Fernanda Milanezi Rui M Reis Fernando Schmitt

Gastrointestinal stromal tumors (GISTs) are characterized by overexpression and mutations of c-Kit. Approximately 80% of c-Kit mutations occur in exon 11, being a response factor to imatinib (Gleevec) therapy. Mutations of platelet-derived growth factor receptor-alpha (PDGFRA) are observed in a subset of GISTs lacking c-Kit mutations.We aimed to assess whether c-Kit and PDGFRA mutation analysis...

Journal: :Cancer research 2005
Sun-Jin Kim Hisanori Uehara Sertac Yazici Junqin He Robert R Langley Paul Mathew Dominic Fan Isaiah J Fidler

Prostate cancer cells metastasize to the bone where their interaction with osteoclasts and osteoblasts can lead to alterations in the structure of the bone. We determined whether the systemic administration of the bisphosphonate, zoledronate, could prevent bone lysis and halt the proliferation of human prostate cancer cells injected into the tibia of nude mice. Zoledronate did not affect the in...

2016
Najla El Jurdi Mark Bankoff Andreas Klein Muhammad W Saif

Imatinib (Gleevec; STI-571) is a tyrosine-kinase inhibitor (TKI) used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most common adverse effects with imatinib include superficial edema, muscle cramps, musculoskeletal pain, rash, fatigue, headache, and gastrointesti...

2016
Stuart D. Dowall Kevin Bewley Robert J. Watson Seshadri S. Vasan Chandradhish Ghosh Mohini M. Konai Gro Gausdal James B. Lorens Jason Long Wendy Barclay Isabel Garcia-Dorival Julian Hiscox Andrew Bosworth Irene Taylor Linda Easterbrook James Pitman Sian Summers Jenny Chan-Pensley Simon Funnell Julia Vipond Sue Charlton Jayanta Haldar Roger Hewson Miles W. Carroll

In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selec...

2009
Hadi Alphonse Goubran

INTRODUCTION Due to high rates of response and durable remissions, imatinib (Glivec((R)), or Gleevec((R)) in the USA; Novartis Pharma AG) is the standard of care in patients with chronic myeloid leukemia. Recently, a non-authorized product which claims comparability to imatinib has become available. CASE PRESENTATION This report describes the loss of response in a 36-year-old male patient wit...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید